Cequent Pharmaceuticals

As an early-stage biopharmaceutical company, Cequent Pharmaceuticals is developing novel therapies to prevent and treat a variety of human diseases, ranging from inflammatory conditions to cancer. Cequent's first products, currently in preclinical development, are candidates for the prevention of colon cancer and treatment of inflammatory bowel disease. The company has designed the powerful tkRNAi technology, which safely and effectively inactivates specific disease-causing genes by using non-pathogenic bacteria as a vehicle to directly deliver RNAi into cells.